The latest price target for Entera Bio (NASDAQ:ENTX) was reported by HC Wainwright & Co. on August 12, 2024. The analyst firm set a price target for $10.00 expecting ENTX to rise to within 12 months (a possible 338.60% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Entera Bio (NASDAQ:ENTX) was provided by HC Wainwright & Co., and Entera Bio reiterated their buy rating.

There is no last upgrade for Entera Bio

There is no last downgrade for Entera Bio.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Entera Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Entera Bio was filed on August 12, 2024 so you should expect the next rating to be made available sometime around August 12, 2025.

While ratings are subjective and will change, the latest Entera Bio (ENTX) rating was a reiterated with a price target of $10.00 to $10.00. The current price Entera Bio (ENTX) is trading at is $2.28, which is out of the analyst’s predicted range.